Polygenic Prediction of Complex Human Traits Arxiv:2101.05870V1

Total Page:16

File Type:pdf, Size:1020Kb

Polygenic Prediction of Complex Human Traits Arxiv:2101.05870V1 From Genotype to Phenotype: polygenic prediction of complex human traits Timothy G. Raben1, Louis Lello1,2, Erik Widen1, and Stephen D.H. Hsu1,2 1Michigan State University, East Lansing, Michigan, 48824 2Genomic Prediction, North Brunswick, New Jersey, 08902 Abstract Decoding the genome confers the capability to predict characteristics of the organism (phenotype) from DNA (genotype). We describe the present status and future prospects of genomic prediction of complex traits in humans. Some highly heritable complex phenotypes such as height and other quantitative traits can already be predicted with reasonable accuracy from DNA alone. For many diseases, including important common conditions such as coro- nary artery disease, breast cancer, type I and II diabetes, individuals with outlier polygenic scores (e.g., top few percent) have been shown to have 5 or even 10 times higher risk than average. Several psychiatric conditions such as schizophrenia and autism also fall into this arXiv:2101.05870v1 [q-bio.GN] 14 Jan 2021 category. We discuss related topics such as the genetic architecture of complex traits, sibling validation of polygenic scores, and applications to adult health, in vitro fertilization (embryo selection), and genetic engineering. A version of this article was prepared for Genomic Prediction of Complex Traits, Springer Nature book series Methods in Molecular Biology. Keywords: genomics, complex trait prediction, PRS, in vitro fertilization, genetic engineering 1 1 Introduction I, on the other hand, knew nothing, except ... physics and mathematics and an ability to turn my hand to new things. — Francis Crick The challenge of decoding the genome has loomed large over biology since the time of Wat- son and Crick. Initially, decoding referred to the relationship between DNA and specic proteins or molecular mechanisms, but the ultimate goal is to deduce the relationship between DNA and phenotype — the character of the organism itself. How does Nature encode the traits of the organ- ism in DNA? In this review we describe recent advances toward this goal, which have resulted from the application of machine learning (ML) to large genomic data sets. Genomic prediction is the real decoding of the genome: the creation of mathematical models which map genotypes to complex traits. It is a peculiarity of ML and articial intelligence (AI) applied to complex systems that these methods can often “solve” a problem without explicating, in a manner that humans can absorb, the intricate mechanisms that lie intermediate between input and output. For example, AlphaGo [1] achieved superhuman mastery of an ancient game that had been under serious study for thousands of years. Yet nowhere in the resulting neural network with millions of connection strengths is there a human-comprehensible guide to Go strategy or game dynamics. Similarly, ge- nomic prediction has produced mathematical functions which predict quantitative human traits with surprising accuracy — e.g., height, bone density, and cholesterol or lipoprotein A levels in blood (see Table 1); using typically thousands of genetic variants as input (see next section for details) — but without explicitly revealing the role of these variants in actual biochemical mech- anisms. Characterizing these mechanisms — which are involved in phenomena such as bone growth, lipid metabolism, hormonal regulation, protein interactions — will be a project which takes much longer to complete. If recent trends persist, in particular the continued growth of large genotype | phenotype data sets, we will likely have good genomic predictors for a host of human traits within the next decade. Here good can mean capturing most of the a priori estimated heritability of the trait. 2 Phenotype Correlation # active SNPs Height 0.639¹0.017º 22, 000¹3000º Heel bone density 0.449¹0.015º 15, 000¹4000º BMI 0.346¹0.0009 22, 000¹2000º Educational attainment 0.272¹0.022º 17, 000¹7000º Apolipoprotein A 0.417¹0.006º 15, 000¹2,000º Apolipoprotein B 0.38¹0.01º 9, 000¹2,000º Cholesterol 0.310¹0.007º 10, 000¹3,000º Direct bilirubin 0.51¹0.01º 4, 000¹4,000º HDL cholesterol 0.46¹0.01º 17, 000¹2,000º Lipoprotein A 0.757¹0.008º 3, 000¹1,000º Platelet count 0.45¹0.01º 15, 000¹800º Total bilirubin 0.56¹0.01º 5, 000¹3,000º Total protein 0.32¹0.01º 15, 000¹1,000º Triglycerides 0.348¹0.008º 11, 000¹4,000º Table 1: Examples of quantitative trait prediction. The last 10 traits listed are all obtained from standard blood test measurements (terminology from UK Biobank data elds). Uncertainties given in parenthesis are the standard deviation obtained from validation of 5 dierent training runs, each of which produce a slightly dierent predictor. Predictors were trained with data and methods analogous to [2]. 3 There are already many disease risk predictors which fall somewhat short of this standard but nevertheless have important practical utility in medicine (e.g., for early screening and diagnosis), as we will discuss below. We can roughly estimate how predictor performance increases as a function of training data size (see gure 1). The estimates suggest that progress is data limited: algorithms and computational resources are not the bottleneck. In the following sections we will discuss (1) Current status of human genomic prediction: examples of quantitative trait prediction and prediction of disease risk, out of sample validation of predictors, sibling validation, (2) Methods, Genetic Architecture, and Theory, and (3) Applications to In Vitro Fertilization and Gene Editing. The nal section will discuss some (near term) future projections. 0.65 ● 0.65 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 0.60 ● 0.60 ● ● ● ● ● ● ● ● AUC ● ● ● 0.55 hypertension 0.55 ● hypothyroidism type 2 diabetes ● 0.50 0.50 0.0 0.5 1.0 1.5 2.0 Log[N/1000] Figure 1: Prediction quality measured by AUC for three conditions (hypertension, hypothy- roidism, type 2 diabetes) as a function of training sample size # . Evidence is strong that further increases in sample size will lead to improvement in accuracy. Reproduced from [2]. 4 2 Present Status: 2020 Technological advances have reduced the (2020) cost of whole genome sequencing to under $1k and the cost of SNP array genotyping to roughly $20 [3]. In this section we will give an overview of results obtained from training on data sets obtained using SNP arrays. For quantitative traits sample sizes were in excess of 400k individuals. For disease risk training (polygenic risk scores, or PRS) typical sample sizes were tens of thousands of cases and at least as many controls, typically individuals late in life for whom medical records are available. See [2] for specic details. 2.1 Quantitative traits: height, bone, and blood In 2012 one of the authors [4] estimated that training on a few hundred thousand SNP genotypes using L1 penalization (see next section for details) would capture most of the common SNP her- itability for height. In 2017, with the release of the UK Biobank data set of 500k genomes, this prediction came true. Accurate genomic prediction of adult height, with standard deviation of ∼ 3 cm, was demonstrated in [5], and has been subsequently replicated by other groups [6, 7], as well as in studies of siblings. See gures 2 and 6 for a demonstration of the prediction accuracy. In 2020 the GIANT collaboration, in a GWAS of roughly 4 million individuals, identied ∼10k height SNPs at genome-wide statistical signicance. The variance accounted for by the L1 pre- dictor and by the predictor produced from the 2020 GIANT GWAS are roughly equal to the pre- viously estimated narrow sense heritability accounted for by common SNPs [8, 9]. Genomic predictors which capture a signicant fraction of heritability exist for other quan- titative traits, including bone density, educational attainment / cognitive abilities, and a number of blood measurements such as platelet count and lipoprotein A levels, see table 1. 2.2 Disease Risks: Polygenic Risk Scores (PRS) Polygenic risk predictors for dozens of important disease conditions, including, e.g., diabetes, breast cancer, coronary artery disease, hypertension, schizophrenia, autism, and many more, 5 190 men women ) 180 cm ( 170 160 Predicted height 150 150 160 170 180 190 200 Measured height(cm) Figure 2: Height prediction in males and females not used in predictor training. Predicted height computed from ∼20k SNPs is shown on vertical axis, and actual height on horizontal axis. In a typical bin the standard deviation of the distribution of actual heights relative to prediction is ∼ 3cm. While it is possible to nd individuals whose height deviates from prediction by signicantly more than a few cm, most of the population density is concentrated close to the prediction line. Correlation between predicted and actual (z-scored) height is ∼ 0.65. Reproduced from [5]. have been published and validated by many research groups [2, 10–12]. We can roughly characterize the performance of these polygenic risk predictors as follows: individuals with very high PRS will typically have an incidence rate which is many times higher than the population average. For example, in [2] we found that for atrial brillation, 99th per- centile PRS implies ∼10 times higher likelihood of case status. Similarly, low PRS indicates below average risk for the condition: we can identify individuals whose risk is an order of magnitude lower than in the general population. 6 Identication of outliers is possible even though the standard performance metric AUC (Area Under ROC Curve) value is modest: e.g., AUC ∼ 0.6. This is because the absolute risk as function of PRS is highly nonlinear: outlier (e.g., 99th percentile) risk can be very high even if risk for individuals near the middle of the PRS distribution varies only modestly — see gure 3, which illustrates risk dierentiation for the example phenotypes breast cancer and hypothyroidism. We report below on further explicit results.
Recommended publications
  • Interpreting Noncoding Genetic Variation in Complex Traits and Human Disease
    REVIEW Interpreting noncoding genetic variation in complex traits and human disease Lucas D Ward1,2 & Manolis Kellis1,2 Association studies provide genome-wide information about the genetic basis of complex disease, but medical research has focused primarily on protein-coding variants, owing to the difficulty of interpreting noncoding mutations. This picture has changed with advances in the systematic annotation of functional noncoding elements. Evolutionary conservation, functional genomics, chromatin state, sequence motifs and molecular quantitative trait loci all provide complementary information about the function of noncoding sequences. These functional maps can help with prioritizing variants on risk haplotypes, filtering mutations encountered in the clinic and performing systems-level analyses to reveal processes underlying disease associations. Advances in predictive modeling can enable data-set integration to reveal pathways shared across loci and alleles, and richer regulatory models can guide the search for epistatic interactions. Lastly, new massively parallel reporter experiments can systematically validate regulatory predictions. Ultimately, advances in regulatory and systems genomics can help unleash the value of whole-genome sequencing for personalized genomic risk assessment, diagnosis and treatment. Understanding the genetic basis of disease can transform medicine ture of the human genome, and its systematic mapping by the HapMap by elucidating relevant biochemical pathways for drug targets and by Project9, allowed single-nucleotide polymorphisms (SNPs) to be used enabling personalized risk assessments1,2. With the evolution of technol- as markers for common haplotypes, which could be genotyped using ogies over the past century, geneticists are no longer limited to studying chip technology. The stage was set for a flood of unbiased, genome-wide Mendelian disorders and can tackle complex phenotypes.
    [Show full text]
  • Identifying Intergenerational Risk Factors for ADHD Symptoms Using Polygenic Scores in the Norwegian Mother, Father and Child Cohort
    medRxiv preprint doi: https://doi.org/10.1101/2021.02.16.21251737; this version posted February 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Intergenerational transmission of ADHD Identifying intergenerational risk factors for ADHD symptoms using polygenic scores in the Norwegian Mother, Father and Child Cohort Jean-Baptiste Pingault1,2*, Wikus Barkhuizen1*, Biyao Wang1, Laurie J. Hannigan3,4, Espen Moen Eilertsen6, Ole A. Andreassen7, Helga Ask5, Martin Tesli5,7, Ragna Bugge Askeland4,5, George Davey Smith4,9, Neil Davies4,8,9, Ted Reichborn-Kjennerud5, †Eivind Ystrom5,6, †Alexandra Havdahl3,5,6 *Equal first authors †Equal last authors 1 Division of Psychology and Language Sciences, University College London, London, United Kingdom 2 MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King’s College, London, United Kingdom 3 Nic Waals Institute, Lovisenberg Diaconal Hospital, Oslo, Norway 4 Medical Research Council Integrative Epidemiology Unit, University of Bristol, BS8 2BN, United Kingdom 5 Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway 6 PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway 7 NORMENT Centre, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway 8 K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Norway 9 Population Health Sciences, Bristol Medical School, University of Bristol, Barley House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom Address correspondence to Dr.
    [Show full text]
  • Genetics in Harry Potter's World: Lesson 2
    Genetics in Harry Potter’s World Lesson 2 • Beyond Mendelian Inheritance • Genetics of Magical Ability 1 Rules of Inheritance • Some traits follow the simple rules of Mendelian inheritance of dominant and recessive genes. • Complex traits follow different patterns of inheritance that may involve multiples genes and other factors. For example, – Incomplete or blended dominance – Codominance – Multiple alleles – Regulatory genes Any guesses on what these terms may mean? 2 Incomplete Dominance • Incomplete dominance results in a phenotype that is a blend of a heterozygous allele pair. Ex., Red flower + Blue flower => Purple flower • If the dragons in Harry Potter have fire-power alleles F (strong fire) and F’ (no fire) that follow incomplete dominance, what are the phenotypes for the following dragon-fire genotypes? – FF – FF’ – F’F’ 3 Incomplete Dominance • Incomplete dominance results in a phenotype that is a blend of the two traits in an allele pair. Ex., Red flower + Blue flower => Purple flower • If the Dragons in Harry Potter have fire-power alleles F (strong fire) and F’ (no fire) that follow incomplete dominance, what are the phenotypes for the following dragon-fire genotypes: Genotypes Phenotypes FF strong fire FF’ moderate fire (blended trait) F’F’ no fire 4 Codominance • Codominance results in a phenotype that shows both traits of an allele pair. Ex., Red flower + White flower => Red & White spotted flower • If merpeople have tail color alleles B (blue) and G (green) that follow the codominance inheritance rule, what are possible genotypes and phenotypes? Genotypes Phenotypes 5 Codominance • Codominance results in a phenotype that shows both traits of an allele pair.
    [Show full text]
  • The Genetics of Complex Traits Programme Course 7.5 Credits Genetiska Mekanismer Bakom Komplexa Egenskaper 8MEA14 Valid From: 2019 Autumn Semester
    DNR LIU-2019-00662 1(5) The genetics of complex traits Programme course 7.5 credits Genetiska mekanismer bakom komplexa egenskaper 8MEA14 Valid from: 2019 Autumn semester Determined by The Board for First and Second Cycle Programmes at the Faculty of Medicine and Health Sciences Date determined 2019-03-07 LINKÖPING UNIVERSITY FACULTY OF MEDICINE AND HEALTH SCIENCES LINKÖPING UNIVERSITY THE GENETICS OF COMPLEX TRAITS FACULTY OF MEDICINE AND HEALTH SCIENCES 2(5) Main field of study Medical Biology Course level Second cycle Advancement level A1X Course offered for Master's Programme in Experimental and Medical Biosciences Entry requirements Degree of Bachelor of Science, 180 ECTS in a major subject area such as medicine, biology, technology/natural sciences, odontology or veterinary medicine. 90 ECTS of courses included in the Bachelor degree should be in subjects such as biochemistry, cell biology, molecular biology, genetics, gene technology, microbiology, immunology, physiology, histology, anatomy or pathology. Documented skills in English corresponding to level 6/B. Intended learning outcomes The student will learn and understand the basis of quantitative genetic techniques, in particular how they pertain to the identification of genes underlying complex traits and diseases. Knowledge and understanding On completion of the course, the student shall be able to: Describe and understand statistical quantitative genetic techniques and how they apply to complex traits. Explain the statistical basis of quantitative traits. Explain and distinguish between linkage and linkage disequilibrium and their uses. Analyse the genetic architecture of different behavioral and disease-related traits. Analyse and understand the theory and steps required to identify the genetic components of a quantitative trait.
    [Show full text]
  • Common Genetic Variation and Schizophrenia Polygenic Risk
    RESEARCH ARTICLE Neuropsychiatric Genetics Common Genetic Variation and Schizophrenia Polygenic Risk Influence Neurocognitive Performance in Young Adulthood Alex Hatzimanolis,1 Pallav Bhatnagar,2 Anna Moes,2 Ruihua Wang,1 Panos Roussos,3,4 Panos Bitsios,5 Costas N. Stefanis,6 Ann E. Pulver,1 Dan E. Arking,2 Nikolaos Smyrnis,6,7 Nicholas C. Stefanis,6,7 and Dimitrios Avramopoulos1,2* 1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 2McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 3Department of Psychiatry, Friedman Brain Institute and Department of Genetics and Genomics Science, Institute of Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York 4James J. Peters Veterans Affairs Medical Center, Bronx, New York, New York 5Department of Psychiatry and Behavioral Sciences, Faculty of Medicine, University of Crete, Heraklion, Greece 6University Mental Health Research Institute, Athens, Greece 7Department of Psychiatry, Eginition Hospital, University of Athens Medical School, Athens, Greece Manuscript Received: 3 December 2014; Manuscript Accepted: 29 April 2015 Neurocognitive abilities constitute complex traits with consid- erable heritability. Impaired neurocognition is typically ob- How to Cite this Article: served in schizophrenia (SZ), whereas convergent evidence Hatzimanolis A, Bhatnagar P, Moes A, has shown shared genetic determinants between neurocognition Wang R, Roussos P, Bitsios P, Stefanis CN, and SZ. Here, we report a genome-wide association study Pulver AE, Arking DE, Smyrnis N, Stefanis (GWAS) on neuropsychological and oculomotor traits, linked NC, Avramopoulos D. 2015. Common to SZ, in a general population sample of healthy young males Genetic Variation and Schizophrenia ¼ (n 1079).
    [Show full text]
  • Polygenic Methods and Their Application to Psychiatric Traits
    This is the peer reviewed version of the following article: Wray, N. R., & Visscher, P. M. (2015). Quantitative genetics of disease traits. Wray, N. R., Lee, S. H., Mehta, D., Vinkhuyzen, A. A., Dudbridge, F., & Middeldorp, C. M. (2014). Research review: polygenic methods and their application to psychiatric traits. Journal of Child Psychology and Psychiatry, 55(10), 1068–1087. DOI: 10.1111/jcpp.12295 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving. Polygenic methods and their application to psychiatric traits Naomi R Wray1*, S Hong Lee1, Divya Mehta1, Anna AE Vinkhuyzen1, Frank Dudbridge2, Christel M Middeldorp3,4 1. The University of Queensland, Queensland Brain Institute, Queensland, Australia 4068 2. Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK 3. Department of Biological Psychology, Neuroscience Campus Amsterdam, VU University Amsterdam, The Netherlands 4. Department of Child and Adolescent Psychiatry, GGZ inGeest/VU University Medical Center, Amsterdam, The Netherlands * Corresponding author. [email protected] Abstract Background Despite evidence from twin and family studies for an important contribution of genetic factors to both childhood and adult onset psychiatric disorders, identifying robustly associated specific DNA variants has proved challenging. In the pre-genomics era the genetic architecture (number, frequency and effect size of risk variants) of complex genetic disorders was unknown. Empirical evidence for the genetic architecture of psychiatric disorders is emerging from the genetic studies of the last five years. Methods and scope We review the methods investigating the polygenic nature of complex disorders.
    [Show full text]
  • The BRCA1 Tumor Suppressor
    Journal of Translational Science Review Article ISSN: 2059-268X The BRCA1 tumor suppressor: potential long-range interactions of the BRCA1 promoter and the risk of breast cancer Beata Anna Bielinska* Department of Molecular and Translational Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Poland Abstract Breast cancer is a complex disease with different phenotypes associated with genetic and non-genetic risk factors. An aberrant expression of the BRCA1 tumor suppressor as well as dysfunction of BRCA1 protein caused by germline mutations are implicated in breast cancer aethiology. BRCA1 plays a crucial role in genome and epigenome stability. Its expression is auto regulated and modulated by various cellular signals including metabolic status, hypoxia, DNA damage, estrogen stimulation. The review describes breast cancer risk factors, the BRCA1 gene expression and functions as well as covers the role of long-range genomic interactions, which emerge as regulators of gene expression and moderators of genomic communication. The potential long-range interactions of the BRCA1 promoter (driven by polymorphic variant rs11655505 C/T, as an example) and their possible impact on the BRCA1 gene regulation and breast cancer risk are also discussed. Introduction efficiency of BRCA1 transcription [9]. However, to date the mechanism underlying effect of the BRCA1 promoter variant rs11655505 C>T Female breast cancer is one of the most common cancers worldwide remains unknown. with app.1.68 million cases diagnosed annually [1]. It is a complex disease characterized by molecular and phenotypic heterogeneity Besides high risk BRCA1/BRCA2 mutations, moderate risk observed both within populations and intra-individually, within mutations such as those found in DNA repair genes (CHEK2, ATM, single tumor cells in a spatiotemporal manner, as pointed out by PALB2) also demonstrate familial clustering.
    [Show full text]
  • Within-Sibship GWAS Improve Estimates of Direct Genetic Effects
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.05.433935; this version posted March 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Within-sibship GWAS improve estimates of direct genetic effects Laurence J Howe1,2 *, Michel G Nivard3, Tim T Morris1,2, Ailin F Hansen4, Humaira Rasheed4, Yoonsu Cho1,2, Geetha Chittoor5, Penelope A Lind6,7,8, Teemu Palviainen9, Matthijs D van der Zee3, Rosa Cheesman10,11, Massimo Mangino12,13, Yunzhang Wang14, Shuai Li15,16,17, Lucija Klaric18, Scott M Ratliff19, Lawrence F Bielak19, Marianne Nygaard20,21, Chandra A Reynolds22, Jared V Balbona23,24, Christopher R Bauer25,26, Dorret I Boomsma3,27, Aris Baras28, Archie Campbell29, Harry Campbell30, Zhengming Chen31,32, Paraskevi Christofidou12, Christina C Dahm33, Deepika R Dokuru23,24, Luke M Evans24,34, Eco JC de Geus3,35, Sudheer Giddaluru36,37, Scott D Gordon38, K. Paige Harden39, Alexandra Havdahl40,41, W. David Hill42,43, Shona M Kerr18, Yongkang Kim24, Hyeokmoon Kweon44, Antti Latvala9,45, Liming Li46, Kuang Lin31, Pekka Martikainen47,48,49, Patrik KE Magnusson14, Melinda C Mills50, Deborah A Lawlor1,2,51, John D Overton27, Nancy L Pedersen14, David J Porteous25, Jeffrey Reid28, Karri Silventoinen47, Melissa C Southey17,52,53, Travis T Mallard39, Elliot M Tucker-Drob39, Margaret J Wright54, Social Science Genetic Association Consortium, Within Family
    [Show full text]
  • LDL Polygenic Risk Scores in Practice
    University of Copenhagen & Copenhagen University Hospital LDL polygenic risk scores in practice Anne Tybjærg-Hansen MD DMSc Professor, Chief Physician Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark FH Global Summit, Atlanta 211019 Outline • Introduction to polygenic risk score • Polygenic risk scores for LDL cholesterol and FH • Polygenic risk scores for CAD and FH – polygenic versus omnigenic scores • Take home message Introduction to polygenic risk score Genome-wide association study of LDL cholesterol (from GLGC) P<10-8 Willer CJ et al. Nat Genet 2013 Creating a polygenic score GWAS SNPs Individually: tiny effects ComBined: larger effect Effect of gene score on trait level 1.0 1.2 Odds ratio Genome-wide association study of LDL cholesterol Polygenic risk score P<10-8 Willer CJ et al. Nat Genet 2013 Genome-wide association studies (GWAS’) for lipids In sufficiently large samples, many ~ 100,000 previously non-significant loci would European ancestry become nominally significant, 95 loci although effect sizes are close to zero. ~ 600,000 ~85,000 non-Europeans ~200,000 >118 novel loci 7,898 non-Europeans (~268 known loci) 62 novel loci 30.4 mill SNPs Klarin et al. 2010 2013 2018 Polygenic risk scores for LDL cholesterol and Familial Hypercholesterolemia Rigshospitalet The Centre of Diagnostic Investigations Diagnostic criteria for FH 1/220 individuals • Definite FH: > 8 points • Probable FH: 6-8 points • Possible FH: 3-5 points • Unlikely FH: 0-2 points Mette Christoffersen 9 Rigshospitalet The Centre of Diagnostic Investigations Clinical vs. mutation diagnosis Polygenic cause? 20-40% High Lp(a)? 60-80 % Polygenic cause? Modified from Eur Heart J.
    [Show full text]
  • Selection Against Variants in the Genome Associated PNAS PLUS with Educational Attainment
    Selection against variants in the genome associated PNAS PLUS with educational attainment Augustine Konga,b,1, Michael L. Friggea, Gudmar Thorleifssona, Hreinn Stefanssona, Alexander I. Youngc, Florian Zinka, Gudrun A. Jonsdottira, Aysu Okbayd,e, Patrick Sulema, Gisli Massona, Daniel F. Gudbjartssona,b, Agnar Helgasona,f, Gyda Bjornsdottira, Unnur Thorsteinsdottira,g, and Kari Stefanssona,g,1 adeCODE genetics/Amgen Inc., Reykjavik 101, Iceland; bSchool of Engineering and Natural Sciences, University of Iceland, Reykjavik 101, Iceland; cWellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom; dDepartment of Applied Economics, Erasmus School of Applied Economics, Erasmus University Rotterdam, 3062 PA Rotterdam, The Netherlands; eInstitute for Behavior and Biology, Erasmus University Rotterdam, 3062 PA Rotterdam, The Netherlands; fDepartment of Anthropology, University of Iceland, Reykjavik 101, Iceland; and gFaculty of Medicine, University of Iceland, Reykjavik 101, Iceland Edited by Andrew G. Clark, Cornell University, Ithaca, NY, and approved December 5, 2016 (received for review July 22, 2016) Epidemiological and genetic association studies show that genet- 62 cohorts were used to determine the weightings for POLYEDU. ics play an important role in the attainment of education. Here, we We computed POLYEDU for over 150,000 Icelanders who were investigate the effect of this genetic component on the reproduc- directly genotyped with chip arrays and imputed for additional tive history of 109,120 Icelanders and the consequent impact on sequence variants discovered through whole-genome sequencing the gene pool over time. We show that an educational attainment of 8,453 Icelanders (20) (Materials and Methods). POLYEDU was polygenic score, POLYEDU, constructed from results of a recent scaled to an SD of 1, hereafter referred to as standard units (SUs).
    [Show full text]
  • Genetic Analysis of Complex Traits in the Emerging Collaborative Cross
    Downloaded from genome.cshlp.org on October 5, 2021 - Published by Cold Spring Harbor Laboratory Press Research Genetic analysis of complex traits in the emerging Collaborative Cross David L. Aylor,1 William Valdar,1,13 Wendy Foulds-Mathes,1,13 Ryan J. Buus,1,13 Ricardo A. Verdugo,2,13 Ralph S. Baric,3,4 Martin T. Ferris,1 Jeff A. Frelinger,4 Mark Heise,1 Matt B. Frieman,4 Lisa E. Gralinski,4 Timothy A. Bell,1 John D. Didion,1 Kunjie Hua,1 Derrick L. Nehrenberg,1 Christine L. Powell,1 Jill Steigerwalt,5 Yuying Xie,1 Samir N.P. Kelada,6 Francis S. Collins,6 Ivana V. Yang,7 David A. Schwartz,7 Lisa A. Branstetter,8 Elissa J. Chesler,2 Darla R. Miller,1 Jason Spence,1 Eric Yi Liu,9 Leonard McMillan,9 Abhishek Sarkar,9 Jeremy Wang,9 Wei Wang,9 Qi Zhang,9 Karl W. Broman,10 Ron Korstanje,2 Caroline Durrant,11 Richard Mott,11 Fuad A. Iraqi,12 Daniel Pomp,1,14 David Threadgill,5,14 Fernando Pardo-Manuel de Villena,1,14 and Gary A. Churchill2,14 1Department of Genetics, University of North Carolina–Chapel Hill, Chapel Hill, North Carolina 27599, USA; 2The Jackson Laboratory, Bar Harbor, Maine 04609, USA; 3Department of Epidemiology, University of North Carolina–Chapel Hill, Chapel Hill, North Carolina 27599, USA; 4Department of Microbiology and Immunology, University of North Carolina–Chapel Hill, Chapel Hill, North Carolina 27599, USA; 5Department of Genetics, North Carolina State University, Raleigh, North Carolina 27695, USA; 6Genome Technology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland
    [Show full text]
  • Dr. David Reeb
    Dr. David Reeb Personal Data Address: Institute for Theoretical Physics Leibniz Universitat¨ Hannover Appelstr. 2 30167 Hannover, Germany Place and date of birth: Ellwangen, Germany, 4th October 1981 Citizenship: German Office phone: +49 (0)511 762 17508 Email: [email protected] Website: www.itp.uni-hannover.de/Gruppen/quinfo/dreeb/ Fields of Specialization Quantum Information: information and communication theory, entanglement, quantum thermody- namics, dissipative state preparation, underlying mathematical structures Mathematical Physics: statistical physics, Markov chains and master equations, equilibration, ma- trix analysis and operator algebras Applied Mathematics: convex optimization, polynomial optimization hierarchies, algebraic geom- etry, including computational methods Professional Experience 12/2014 – present Postdoctoral Researcher, Quantum Information group (Prof. R. Werner) Institute for Theoretical Physics, Leibniz Universitat¨ Hannover, Germany 12/2012 – 11/2014 Marie Curie Fellow, Intra-European Fellowship Department of Mathematics, Technische Universitat¨ Munchen,¨ Germany 05/2011 – 11/2012 Postdoctoral Researcher, Mathematical Physics group (Prof. M. Wolf) Department of Mathematics, Technische Universitat¨ Munchen,¨ Germany 07/2010 – 04/2011 Postdoctoral Researcher, Quantum Information group (Prof. M. Wolf) Niels Bohr Institute, University of Copenhagen, Denmark 09/2006 – 06/2010 PhD Student, Institute for Theoretical Science (Prof. Stephen Hsu) Department of Physics, University of Oregon, Eugene, USA
    [Show full text]